How to buy Vaxart stock (VXRT)

Vaxart is a biotechnology business based in the US. Vaxart shares (VXRT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.54 – a decrease of 9.47% over the previous week. Vaxart employs 109 staff and has a trailing 12-month revenue of around $13.9 million.

Our top picks for where to buy Vaxart stock

Buy Vaxart stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Vaxart stock price (NASDAQ: VXRT)

Use our graph to track the performance of VXRT stocks over time.

Vaxart shares at a glance

• Key figures

Information last updated 2024-12-11.

Latest market close	$0.54
52-week range	$0.52 - $1.54
50-day moving average more info button	$0.72
200-day moving average more info button	$0.82
Wall St. target price	$4.83
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.40

Is it a good time to buy Vaxart stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vaxart price performance over time

Historical closes compared with the close of $0.5907 from 2024-12-17

1 week (2024-12-12)	-0.97%
1 month (2024-11-19)	-4.73%
3 months (2024-09-19)	-34.81%
6 months (2024-06-18)	-13.59%

1 year (2023-12-19)	-3.67%
2 years (2022-12-19)	-34.82%
3 years (2021-12-17)	7.2
5 years (2019-12-19)	93.42%

Vaxart financials

Revenue TTM	$13.9 million
Gross profit TTM	$-80,947,000
Return on assets TTM	-39.68%
Return on equity TTM	-91.66%
Profit margin	0%
Book value	$0.38
Market Capitalization more info button	$139.5 million

TTM: trailing 12 months

Vaxart share dividends

We're not expecting Vaxart to pay a dividend over the next 12 months.

Have Vaxart's shares ever split?

Vaxart's shares were split on a 1:11 basis on 13 February 2018 . So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaxart shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Vaxart shares which in turn could have impacted Vaxart's share price.

Vaxart share price volatility

Over the last 12 months, Vaxart's shares have ranged in value from as little as $0.52 up to $1.54. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaxart's is 0.703. This would suggest that Vaxart's shares are less volatile than average (for this exchange).

Vaxart overview

Vaxart, Inc. , a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI. 1 and GII. 4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.

Frequently asked questions

What percentage of Vaxart is owned by insiders or institutions?
Currently 0.87% of Vaxart shares are held by insiders and 17.805% by institutions. How many people work for Vaxart?
Latest data suggests 109 work at Vaxart. When does the fiscal year end for Vaxart?
Vaxart's fiscal year ends in December. Where is Vaxart based?
Vaxart's address is: 170 Harbor Way, South San Francisco, CA, United States, 94080 What is Vaxart's ISIN number?
Vaxart's international securities identification number is: US92243A2006 What is Vaxart's CUSIP number?
Vaxart's Committee on Uniform Securities Identification Procedures number is: 656755105